top of page

Now recruiting patients with early Alzheimer's disease for a Phase IIa clinical trial!

We are currently recruiting patients aged 50-80 years old with a clinical diagnosis of early Alzheimer's disease for our new clinical trial, AntiRetroviral Therapy for Alzheimer's Disease (ART-AD). The study is based on our previous findings that pathological forms of tau activate retrotransposons, or "jumping genes," and that such jumping gene activation is toxic to brain cells. The seven-month trial involves eight visits to the clinic and six months of treatment with 3TC, a drug that is widely prescribed for HIV and Hepatitis B. Please visit our study website for more information:


bottom of page